Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ: SABS) to support the process development and manufacturing of SAB-142, SAB BIO’s ...

The consensus price target for Emergent BioSolutions has shifted from US$15 to US$12, with the modeled fair value sitting at US$12 per share. Analysts link this move to reduced earnings expectations ...

CME Group, the world's leading derivatives marketplace, today reported its April 2026 average daily volume (ADV) reached 25.9 million contracts. Market statistics are available in greater detail at ...

Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will ...

It’s clear that AI is having a more profound impact on an increasing number of industries. In healthcare, finance and ...

When Leah Williamson leaves the Emirates dressing-room, she glances at one of the photos on the wall. It’s of Williamson and ...

Mikel Arteta furiously hit out at the decision to overturn a penalty for Eberechi Eze in Arsenal's draw with Atletico Madrid.

Declan Rice’s furious reaction to Arsenal’s overturned penalty against Atletico Madrid has been caught on camera, with the ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Q1 2026 earnings call highlights: revenue, EBITDA, guidance, NARCAN and international MCM growth, plus debt moves—read now.

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process ...